With its launch in August 2016, Zinbryta became the 14thdisease-modifying therapy (DMT) approved to treat relapsing forms of multiple sclerosis (MS) in the United States. The monoclonal antibody boasts solid efficacy, infrequent dosing, and a novel anti-inflammatory mechanism of action, but the potential for serious long-term side effects has led to a restrictive U.S. label. DRG’s launch-tracking series will examine how the perception and performance of Zinbryta have evolved in the year since its launch in an MS market that, on the one hand, is increasingly transformed by a growing array of DMTs with compelling risk-benefit profilesbut, on the other hand, can and will support a clinical role for each new agent in treating a heterogeneous disease with a complex natural history.

What you will learn in this content:

  • What is U.S. neurologists’ awareness of and familiarity with Zinbryta, and what are their perceptions of the product?
  • To which patients are Zinbryta prescribers prescribing the drug, what are their reasons for prescribing it, and how satisfied are they with it?
  • What are the promotional messages and activities that Biogen and AbbVie are using to support the Zinbryta launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How are the trial and adoption of Zinbryta tracking compared with other product launches in the MS market?

Methodology: ~75-100 U.S. neurologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, ten of these specialists participated in a 30-minute follow-up qualitative interview.

Key drugs: Zinbryta, Lemtrada, Tysabri, Ocrevus, Gilenya, Tecfidera, Copaxone, beta-interferons

Key companies: Biogen, AbbVie, Sanofi Genzyme, Novartis, Teva, Roche/Genentech

Related reports: Emerging Therapies: Ocrevus (Relapsing MS and PP-MS companion series), Emerging Therapies: Lemtrada

Table of contents

  • Multiple Sclerosis - Emerging Therapies - Zinbryta Launch Tracking Wave 3 (US)
    • Key Findings
      • Benchmarking Zinbryta's Launch Success vs. the Competition
        • Awareness of Zinbryta Has Improved, but the Drug Lags Behind Benchmark DMTs on Several Attributes at One Year Postlaunch
        • Benchmarking Zinbryta's Launch Success vs. That of Other Launched Drugs
      • Prescriber and Nonprescriber Profiles
        • Differences Between Zinbryta Prescribers and Nonprescribers
        • Differences Between Zinbryta Prescriber and Nonprescriber Profiles
      • Zinbryta Awareness and Perceptions
        • Unaided and Aided Awareness of Zinbryta
          • Unaided and Aided Awareness of Zinbryta Remains Behind Benchmark DMTs at One Year Postlaunch
          • Unaided Awareness of Drugs Approved or Launched for the Treatment of RR-MS
          • Aided Awareness of Zinbryta
        • Familiarity with Zinbryta
          • Awareness of Zinbryta's Attributes Remains Stable at One Year Postlaunch
          • Level of Familiarity with Zinbryta
          • Mean Level of Familiarity with Zinbryta
          • Aided Awareness of Zinbryta's Indication
          • Aided Awareness of the General Line-of-Therapy Recommendation
          • Aided Awareness of Zinbryta's Dosing Interval
        • Sources of Familiarity with Zinbryta
          • Academic Journals and Medical Meetings Help Drive Zinbryta Familiarity at One Year Postlaunch
        • Initial Reaction to and Interest in Zinbryta
          • Neurologists' Initial Reaction and Interest in Learning More About Zinbryta Waning at One Year Postlaunch
          • Zinbryta Product Profile
          • Zinbryta Information Requiring Additional Education
          • Initial Reaction to Zinbryta
          • Level of Interest in Learning More About Zinbryta
        • Impressions of Zinbryta
          • Neurologists' Concerns About Zinbryta's Side-Effect Profile Have Not Abated at One Year Postlaunch
          • Unaided Advantages of Zinbryta
          • Unaided Disadvantages of Zinbryta
          • Rating of Zinbryta's Risk-Benefit Balance
          • Statement Agreements Regarding Zinbryta's Clinical Profile
          • Physician Quotes on the Advantages and Disadvantages of Zinbryta
          • Physician Quotes on the Role of Zinbryta in Treatment
        • Prescriber and Nonprescriber Profiles
          • Nonprescribers Remain Less Comfortable Managing Zinbryta Risks
          • Differences Between Zinbryta Prescriber and Nonprescriber Profiles
      • Zinbryta Trial and Use
        • Willingness to Prescribe Zinbryta
          • Willingness to Prescribe Zinbryta Has Not Increased with Time
          • Willingness to Prescribe Zinbryta to MS Patients
          • Impact of Clinical and Nonclinical Attributes on Willingness to Prescribe Zinbryta
          • Enrollment in the Zinbryta REMS
          • Ease of Enrollment in the Zinbryta REMS
        • Number of Patients Currently Receiving Zinbryta
          • Use of Zinbryta May Be Shifting to Fourth or Later Lines of Therapy due to Physicians' Safety Concerns
          • Current DMT Patient Shares Among RR-MS Patients
          • Zinbryta Prescriber Base
          • Average Zinbryta Patient Volume
          • Zinbryta Discontinuation Rate
          • Reasons for Discontinuation of Zinbryta
          • Source of Business for Current Zinbryta Patients
          • Source of Therapy for Current Patients Who Were Switched to Zinbryta
          • Number of Prior DMTs for Patients Switched to Zinbryta
          • Current Zinbryta Prescribing by Disease Classification
          • Reasons for Starting/Switching to Zinbryta
          • Zinbryta Follow-Up Visits
          • Zinbryta Treatment Response
          • Percentage of Patients Ever Treated with Zinbryta Who Experienced Select Adverse Events
          • Top Three Obstacles to Prescribing Zinbryta More Frequently
          • Physician Quotes on Current Use of Zinbryta
          • Percentage of Neurologists Receiving a Patient Request for Zinbryta in the Past Month
          • Mean Number of Patients Requesting Zinbryta in the Past Month
          • Action Based on Specific Zinbryta Patient Requests in the Past Month
        • Reasons for Not Yet Prescribing Zinbryta
          • Safety Concerns Continue to Hinder Zinbryta Prescribing at One Year Postlaunch
          • Reasons for Never Prescribing Zinbryta
        • Anticipated Zinbryta Use
          • Zinbryta's Anticipated Patient Share Continues to Increase but Will Be Constrained by Ocrevus
          • Anticipated Timing for Zinbryta Prescribing Among Current Nonprescribers
          • Percentage of MS Patients Who Are Zinbryta Candidates by Disease Classification
          • Percentage of MS Patients Who Are Zinbryta Candidates by Treatment Situation
          • Current and Anticipated DMT Treatment Rate
          • Current and Anticipated Brand Allocation Among DMT-Treated RR-MS Patients
        • Zinbryta Performance on Key Attributes
          • Prescribers Continue to Favorably Rate Zinbryta's Performance on Dosing Schedule and Efficacy
          • Overall Satisfaction with Zinbryta Among Prescribers
          • Rating of Zinbryta's Performance on Clinical and Nonclinical Attributes
          • Physician Quotes on Zinbryta Performance on Key Attributes
      • Effectiveness of Face-to-Face Detailing for Zinbryta
        • Frequency and Reach of Zinbryta Sales Representatives
          • At One Year Postlaunch, the Majority of Surveyed Neurologists Report Contact with a Zinbryta Representative Within the Past Three Months
          • Detailing Reach of Sales Representatives
          • Detailing Visits by Marketing Company
        • Satisfaction with Zinbryta Sales Representative
          • Neurologists Continue to Be Satisfied with Zinbryta's Sales Representatives
          • Satisfaction with Zinbryta's Sales Representative
        • Zinbryta Message Recall
          • Zinbryta Messaging at One Year Postlaunch Appears Focused on Efficacy and Risk
          • Unaided Zinbryta Message Recall During Recent Detail
          • Aided Zinbryta Message Recall During Recent Detail
      • Methodology
        • Primary Market Research Methodology
        • U.S. Region of Practice
        • Patient Allocation by MS Disease Classification
        • Current Drug Treatment Rate in RR-MS
        • Years in Practice Postresidency
        • Practice Setting
        • Practice Location
      • Appendix
        • Abbreviations

    Author(s): Sarah Soucy

    Sarah Soucy, M.S., is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis.

    Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her B.S. in Animal Science with a Bioscience and Technology option and her M.S. in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism


    Related Reports

    Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

    The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

    View Details

    Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

    The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

    View Details

    Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

    Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

    View Details

    Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

    With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

    View Details